Overall Survival | ||
---|---|---|
Univariate Analysis | Multivariate Analysis | |
VARIABLE (Comparator) | HR (95% CI); p – value | HR (95% CI); p - value |
BMI ≥ 25 vs < 25 | 0.33 (0.28–0.41); p < 0.0001 | 0.49 (0.38–0.64); p < 0.0001 |
Weighta | 0.97 (0.96–0.97); p < 0.0001 | 0.99 (0.99–1.01); p = 0.1884 |
irAEs of any grade Yes vs No | 0.45 (0.37–0.54); p < 0.0001 | 0.82 (0.65–1.04); p = 0.1085 |
Primary Tumor (NSCLC) | ||
Melanoma | 0.49 (0.38–0.64); p < 0.0001 | 0.67 (0.51–0.87); p = 0.0036 |
Kidney | 0.56 (0.42–0.74); p = 0.0001 | 0.61 (0.45–0.80); p = 0.0005 |
Others | 1.11 (0.62–1.96); p = 0.7337 | 0.71 (0.40–1.28); p = 0.2632 |
Sex Male vs Female | 1.50 (1.23–1.83); p < 0.0001 | 1.33 (1.09–1.63); p = 0.0044 |
Age Elderly vs Non-elderly | 1.11 (0.93–1.32); p = 0.2401 | – |
Treatment line Non-first vs First | 1.58 (1.26–1.97); p = 0.0001 | 1.42 (1.15–1.77); p = 0.0012 |
N° of metastatic sites > 2 vs ≤ 2 | 1.52 (1.29–1.78); p < 0.0001 | 1.41 (1.17–1.69); p = 0.0002 |
ECOG PS ≥2 vs 0–1 | 2.07 (1.87–2.29); p < 0.0001 | 2.59 (2.09–3.21); p < 0.0001 |